Axsome Therapeutics Engages in Key Investor Conferences Soon
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is continually striving to enhance the treatment landscape for central nervous system (CNS) disorders. The company has exciting news to share as it prepares to participate in three notable investor conferences taking place in June.
Upcoming Investor Conferences
These conferences are a fantastic opportunity for Axsome to connect with investors and industry experts, showcasing its innovative approaches in addressing CNS conditions. Below is a breakdown of the important events:
William Blair Annual Growth Stock Conference
On June 3rd, Axsome will be making its mark at the William Blair 45th Annual Growth Stock Conference, where it will present at 10:40 a.m. CT. This event is poised to bring together investors focused on future growth in the healthcare sector.
Jefferies Global Healthcare Conference
Following this, the company will present at the Jefferies Global Healthcare Conference on June 5th at 2:35 p.m. ET. This gathering is known for assembling key stakeholders from around the globe to discuss advancements in healthcare.
Goldman Sachs Annual Global Healthcare Conference
Lastly, on June 9th, Axsome will attend the Goldman Sachs 46th Annual Global Healthcare Conference, presenting at 2:40 p.m. ET. This will be another significant platform to share the company’s progress and vision.
Accessing Live Presentations
For those unable to attend in person, Axsome Therapeutics will provide live webcasts of each of these presentations. Interested parties can find the webcasts on the "Webcasts & Presentations" section of the company’s website at axsome.com. Additionally, replays will be available for a month following each event, ensuring that no one misses out on the insights shared.
About Axsome Therapeutics
As a pioneering biopharmaceutical company, Axsome Therapeutics aims to advance the treatment of CNS disorders with a dedicated focus on bridging gaps in healthcare. The firm is committed to developing products that leverage unique mechanisms of action, offering hope for meaningful improvements in patient outcomes.
Its impressive neuroscience portfolio features FDA-approved medications for major depressive disorder and excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, among others. With multiple late-stage development programs in progress, Axsome is tackling serious neurological and psychiatric conditions that affect millions across the nation.
Axsome Therapeutics remains focused on its mission: to address some of the most challenging issues in brain health, making life better for patients and their families.
Frequently Asked Questions
What is the significance of the upcoming investor conferences for Axsome Therapeutics?
These conferences are crucial for Axsome Therapeutics to showcase its innovations, connect with investors, and share insights about its future direction in CNS healthcare.
When are the presentations scheduled?
The presentations at the investor conferences are scheduled for June 3rd, June 5th, and June 9th, with specific times announced for each event.
How can the public access the company's presentations?
Live webcasts of the presentations will be available on Axsome’s website, along with replays accessible for about 30 days after each event.
What does Axsome Therapeutics focus on?
Axsome is dedicated to developing treatments for CNS disorders and has a portfolio that includes FDA-approved therapies for major depressive disorder and other sleep-related conditions.
Who can be contacted for investor inquiries?
Mark Jacobson, Chief Operating Officer, can be contacted for investor inquiries. His phone number is (212) 332-3243 and he can be reached via email.
